USC NORRIS CANCER HOSPITAL — History
CCN 050660 | 3-year financial timeline | COVID resilience: 75/100
🛡️ Public data only — no PHI permitted on this instance.
$469M
Latest Revenue (FY2022)
+29.2%
Revenue CAGR (3yr)
19.1%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $281M | $84M | $469M | +459.9% | +29.2% |
| Operating Expenses | $241M | $73M | $379M | +420.8% | +25.3% |
| Operating Margin | 13.9% | 13.0% | 19.1% | +46.6% | +17.1% |
| Net Income | $39M | $11M | $89M | +721.1% | +51.3% |
| Licensed Beds | 60 | 60 | 60 | +0.0% | +0.0% |
| Total Patient Days | 12,131 | 3,057 | 13,192 | +331.5% | +4.3% |
| Medicare Day % | 21% | 28% | 24% | -14.0% | +6.5% |
| Medicaid Day % | 17% | 15% | 16% | +4.3% | -2.7% |
COVID Impact & Recovery
Resilience Score: 75/100 — Resilient — strong COVID recovery
Revenue recovery from FY2020 to FY2022: +67.0% ($281M → $469M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▲ Growing
Beds▶ Stable
Medicare Mix▼ Declining
vs State Average ()
Revenue Growth
+29.2%
This Hospital
+7.6%
State Avg
Latest Margin
19.1%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $563M | 21.7% |
| FY2024 (proj) | $657M | 24.3% |
| FY2025 (proj) | $751M | 26.8% |